Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Severe posttraumatic stress disorder (PTSD) is a prevalent and debilitating condition in the United States. and globally. Using pooled efficacy data from six phase 2 trials, therapy using 3,4-methylenedioxymethamphetamine (MDMA) appeared cost-saving from a payer’s perspective. This study updates the cost-effectiveness analysis of this novel therapy using data from a new phase 3 trial, including the incremental cost-effectiveness of the more intensive phase 3 regimen compared with the shorter phase 2 regimen. Methods: We adapted a previously-published Markov model to portray the costs and health benefits of providing MDMA-assisted therapy (MDMA-AT) to patients with chronic, severe, or extreme PTSD in a recent phase 3 trial, compared with standard care. Inputs were based on trial results and published literature. The trial treated 90 patients with a clinician administered PTSD scale (CAPS-5) total severity score of 35 or greater at baseline, and duration of PTSD symptoms of 6 months or longer. The primary outcome was assessed 8 weeks after the final experimental session. Patients received three 90-minute preparatory psychotherapy sessions, three 8-hour active MDMA or placebo sessions, and nine 90-minute integrative psychotherapy sessions. Our model calculates the per-patient cost of MDMA-AT, net all-cause medical costs, mortality, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs). We reported results from the U.S. health care payer’s perspective for multiple analytic time horizons, (base-case is 30 years), and conducted extensive sensitivity analyses. Costs and QALYs were discounted by 3% annually. Costs were adjusted to 2020 U.S. dollars according to the medical component of the U.S. Bureau of Labor Statistics’ Consumer Price Index (CPI). Results: MDMA-AT as conducted in the phase 3 trial costs $11,537 per patient. Compared to standard of care for 1,000 patients, MDMA-AT generates discounted net health care savings of $132.9 million over 30 years, accruing 4,856 QALYs, and averting 61.4 premature deaths. MDMA-AT breaks even on cost at 3.8 years while delivering 887 QALYs. A third MDMA session generates additional medical savings and health benefits compared with a two-session regimen. Hypothetically assuming no savings in health care costs, MDMA-AT has an ICER of $2,384 per QALY gained. Conclusions: MDMA-AT provided to patients with severe or extreme chronic PTSD is cost-saving from a payer’s perspective, while delivering substantial clinical benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mithoefer, M. C., Feduccia, A. A., Jerome, L., Mithoefer, A., Wagner, M., Walsh, Z., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05249-5 · Cited by 359
RetractedKessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052 · cited 1×
“8 million Americans based on past-year prevalence estimates, and a large portion suffer debilitating effects [1].”
BackgroundWeathers, F. W., Bovin, M. J., Lee, D. J., Sloan, D. M., Schnurr, P. P., Kaloupek, D. G., Keane, T. M., & Marx, B. P. (2018) · Psychological Assessment · doi:10.1037/pas0000486 · Cited by 1,799 · cited 1×
“04), where “severe” is defined as a total score of 35–47 [10].”
MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G., M., Garas, W., Paleos, C., Gorman, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01336-3 · Cited by 1,004
Self-citationPsychological therapies for chronic post-traumatic stress disorder (PTSD) in adults
Bisson, J. I., Roberts, N. P., Andrew, M., Cooper, R., & Lewis, C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003388.pub4 · Cited by 829
Treating PTSD: A Review of Evidence-Based Psychotherapy Interventions
Watkins, L. E., Sprang, K. R., & Rothbaum, B. O. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00258 · Cited by 563
Oehen, P., Traber, R., Widmer, V., & Schnyder, U. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112464827 · Cited by 400 · cited 1×
“MDMA sessions was noted in a small randomized pilot study in which a statistically significant difference in CAPS scores was found between MDMA sessions 2 and 3 [21].”
BackgroundUnited States Valuation of EQ-5D-5L Health States Using an International Protocol
Pickard, A. S., Law, E. H., Jiang, R., Pullenayegum, E., Shaw, J. W., Xie, F., Oppe, M., Boye, K. S., Chapman, R. H., Gong, C. L., et al. (2019) · Value in Health · doi:10.1016/j.jval.2019.02.009 · Cited by 389
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar-Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 376
Trajectories of PTSD: A 20-Year Longitudinal Study
Solomon, Z., & Mikulincer, M. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.659 · Cited by 343
Morina, N., Wicherts, J. M., Lobbrecht, J., & Priebe, S. (2014) · Clinical Psychology Review · doi:10.1016/j.cpr.2014.03.002 · Cited by 314
Health Care Costs Associated With Posttraumatic Stress Disorder Symptoms in Women
Walker, E. A., Katon, W., Russo, J., Ciechanowski, P., Newman, E., & Wagner, A. W. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.4.369 · Cited by 233 · cited 1×
“PTSD is associated with higher mental health and general medical care costs, and costs increase with severity [18].”
BackgroundSavoca, E., & Rosenheck, R. (2000) · The Journal of Mental Health Policy and Economics · doi:10.1002/mhp.102 · Cited by 168
Gutner, C. A., Gallagher, M. W., Baker, A. S., Sloan, D. M., & Resick, P. A. (2016) · Psychological Trauma: Theory, Research, Practice, and Policy · doi:10.1037/tra0000062 · Cited by 126
Steinert, C., Hofmann, M., Leichsenring, F., & Kruse, J. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1005023 · Cited by 115
MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., et al. (2023) · Focus · doi:10.1176/appi.focus.23021011 · Cited by 93
Self-citationMarseille, E., Kahn, J. G., Yazar-Klosinski, B., & Doblin, R. (2020) · PLOS ONE · doi:10.1371/journal.pone.0239997 · Cited by 56 · cited 4×
“medical care payers for patients with PTSD [7].”
BackgroundMethodInfluentialSelf-citationHaviland, M. G., Banta, J. E., Sonne, J. L., & Przekop, P. (2015) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000432 · Cited by 21 · cited 1×
“In addition to the direct human toll, PTSD imposes a large economic burden on the country in added health care costs [2] lower productivity, and higher rates of unemployment [3].”
Background
Cited by
Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
Haikazian, S., Chen-Li, D. C. J., Johnson, D. E., Fancy, F., Levinta, A., Husain, M. I., Mansur, R. B., McIntyre, R. S., & Rosenblat, J. D. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115531 · Cited by 134
Beyond the 5-HT2AReceptor: Classic and Nonclassic Targets in Psychedelic Drug Action
Cameron, L. P., Benetatos, J., Lewis, V., Bonniwell, E. M., Jaster, A. M., Moliner, R., Castrén, E., McCorvy, J. D., Palner, M., & Aguilar-Valles, A. (2023) · The Journal of Neuroscience · doi:10.1523/jneurosci.1384-23.2023 · Cited by 93
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Zaretsky, T. G., Jagodnik, K. M., Barsic, R., Antonio, J. H., Bonanno, P. A., MacLeod, C., Pierce, C., Carney, H., Morrison, M. T., Saylor, C. F., et al. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666231027111147 · Cited by 104
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“As an example, the widespread adoption of MDMA will be limited by its well-known potential for abuse [14], the high cost of a rather complex therapeutic package [15], and a host of neurological, psychiatric, and cardiovascular complications associated with long-term use [16].”
BackgroundMDMA and MDMA-assisted therapy
Wolfgang, A. S., Fonzo, G. A., Gray, J. C., Krystal, J. H., Grzenda, A., Widge, A. S., Kraguljac, N. V., McDonald, W. M., Rodriguez, C. I., & Nemeroff, C. B. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230681 · Cited by 62
Metadata
- Authors
- Marseille, E., Mitchell, J. M., & Kahn, J. G.
- Affiliations
- University of California, Berkeley (US)
- University of California, San Francisco (US)
- Corresponding author
- Marseille, Elliot
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-02-25
- Volume
- 17
- Issue
- 2
- Pages
- e0263252
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8880875
- OpenAlex
- W4214531716
- Cited by
- 50
- References
- 18
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 8 · 2023: 16 · 2022: 4
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-06-02)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Global Brain Health Institute
- Trinity College Dublin
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- MDMA-assisted psychotherapy, MDMA, post-traumatic stress disorder, cost-effectiveness, Markov model, quality-adjusted life years, incremental cost-effectiveness ratio, treatment duration, health care costs, quality of life, payer perspective, integrative psychotherapy, medical cost savings, premature mortality, sensitivity analysis, United States health care system, consumer price index
- MeSH terms
- Adaptation, Physiological, Adult, Cost-Benefit Analysis, Female, Humans, Male, Markov Chains, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, United States, Treatment Outcome, Clinical Trials, Phase III as Topic, N-Methyl-3,4-methylenedioxyamphetamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.